The ASTuTE clinical trial was launched in 2023, led by GenesisCare with investigators from public and private centres, universities and independent urology practices across Australia, to investigate how an AI-based precision medicine test may support shared treatment choices.
The multicentre trial of 786 participants collected real-world data on the effect of a multimodal artificial intelligence (MMAI) biomarker test on treatment decisions for men with intermediate-risk prostate cancer undergoing radiotherapy. Of the 230 men recommended ST-ADT before MMAI testing, 176 - about 3 in 4 - went on to avoid it. The test worked in both directions, also identifying 21 men as likely to benefit who had not been recommended it. Overall, ST-ADT use fell by 20.7%, or roughly one in five men. Researchers also found that clinicians recommended ST-ADT less often as the trial went on, before seeing any test result, suggesting the tool shifted clinical judgement more broadly.
The Artera AI Prostate Test used in the trial provides a prognostic estimate on the patient’s 10-year risk of the cancer spreading, as well as predictive information on the likely benefit of the addition of ST-ADT to radiotherapy for men diagnosed with intermediate risk prostate cancer. The test has been previously validated in a US clinical trial to predict when a patient would benefit from adding ST-ADT and when they would not6.
Read more about the ASTRO 2026 presentation.
